Browse SLC16A3

Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF07690 Major Facilitator Superfamily
Function

Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).

> Gene Ontology
 
Biological Process GO:0006090 pyruvate metabolic process
GO:0006820 anion transport
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015727 lactate transport
GO:0035873 lactate transmembrane transport
GO:0035879 plasma membrane lactate transport
GO:0046942 carboxylic acid transport
GO:0050900 leukocyte migration
GO:0098656 anion transmembrane transport
Molecular Function GO:0005342 organic acid transmembrane transporter activity
GO:0008028 monocarboxylic acid transmembrane transporter activity
GO:0008509 anion transmembrane transporter activity
GO:0008514 organic anion transmembrane transporter activity
GO:0015129 lactate transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0022804 active transmembrane transporter activity
GO:0046943 carboxylic acid transmembrane transporter activity
Cellular Component GO:0005635 nuclear envelope
GO:0015629 actin cytoskeleton
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-210991: Basigin interactions
R-HSA-425471: Bile salt and organic anion SLC transporters
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
R-HSA-1430728: Metabolism
R-HSA-433692: Proton-coupled monocarboxylate transport
R-HSA-70268: Pyruvate metabolism
R-HSA-71406: Pyruvate metabolism and Citric Acid (TCA) cycle
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-1428517: The citric acid (TCA) cycle and respiratory electron transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC16A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC16A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC16A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.8010.00136
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.2260.418
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.4780.425
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.060.922
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1240.956
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0150.996
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0770.905
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3480.824
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2610.876
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8160.733
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4160.91
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.140.289
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC16A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC16A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC16A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC16A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC16A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC16A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC16A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC16A3
Namesolute carrier family 16 (monocarboxylate transporter), member 3
Aliases solute carrier family 16 (monocarboxylic acid transporters), member 3; solute carrier family 16, member 3 (m ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC16A3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SLC16A3.
ID Name Drug Type Targets #Targets
DB00119Pyruvic acidSmall MoleculeABAT, AGXT2, PC, PDHB, PKLR, PKM, SLC16A1, SLC16A2, SLC16A3, SLC16 ......14